Structure Therapeutics Inc. (NASDAQ:GPCR) Given Consensus Rating of “Buy” by Analysts

Structure Therapeutics Inc. (NASDAQ:GPCR) has earned an average recommendation of “Buy” from the seven brokerages that are currently covering the company, Marketbeat Ratings reports. Seven research analysts have rated the stock with a buy recommendation. The average twelve-month target price among analysts that have covered the stock in the last year is $86.50.

Several equities research analysts have recently issued reports on the company. Morgan Stanley initiated coverage on Structure Therapeutics in a report on Monday, September 23rd. They set an “overweight” rating and a $118.00 price objective on the stock. Cantor Fitzgerald reissued an “overweight” rating and issued a $65.00 price target on shares of Structure Therapeutics in a research note on Monday, September 23rd. HC Wainwright reaffirmed a “buy” rating and set a $80.00 price objective on shares of Structure Therapeutics in a research note on Thursday. Finally, JMP Securities reissued a “market outperform” rating and issued a $91.00 target price on shares of Structure Therapeutics in a research report on Wednesday.

Hedge Funds Weigh In On Structure Therapeutics

A number of large investors have recently modified their holdings of the company. Principal Financial Group Inc. acquired a new stake in shares of Structure Therapeutics in the second quarter worth $6,489,000. Natixis Advisors LLC raised its holdings in shares of Structure Therapeutics by 29.4% during the 2nd quarter. Natixis Advisors LLC now owns 19,005 shares of the company’s stock valued at $746,000 after buying an additional 4,321 shares during the period. Gilbert & Cook Inc. purchased a new stake in shares of Structure Therapeutics during the second quarter valued at approximately $229,000. TD Asset Management Inc increased its stake in Structure Therapeutics by 47.9% during the 2nd quarter. TD Asset Management Inc now owns 211,590 shares of the company’s stock worth $8,309,000 after buying an additional 68,490 shares during the period. Finally, Pier Capital LLC lifted its stake in shares of Structure Therapeutics by 3.7% in the second quarter. Pier Capital LLC now owns 101,204 shares of the company’s stock worth $3,974,000 after acquiring an additional 3,647 shares in the last quarter. 91.78% of the stock is currently owned by hedge funds and other institutional investors.

Structure Therapeutics Stock Performance

Shares of NASDAQ GPCR opened at $27.90 on Friday. The firm’s 50 day moving average price is $35.32 and its 200 day moving average price is $38.75. The firm has a market cap of $1.60 billion, a P/E ratio of -37.70 and a beta of -3.41. Structure Therapeutics has a 1 year low of $26.23 and a 1 year high of $62.74.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.